---

title: IV Fluid Formulations for ICU Patients
authors:
    - Michelle Lin, MD
created: 2012/01/03
updates:
categories:
    - Critical Care
---

# Intravenous Fluid Formulations and Chloride-Restrictive IV Fluids for ICU Patients

|  Content per 1 L    | Lactated Ringer's |  Normal Saline (0.9%) | Plasma-Lyte 148 |  D5W | D5 1/2NS |     5% albumin |
| ------------------- | ----------------: | --------------------: | --------------: | ---: | -------: | -------------: |
| Na (mEq)            |               130 |                   154 |             140 |      |       77 |        130-160 |
| K (mEq)             |                 4 |                       |               5 |      |          |         &lt; 1 |
| Cl (mEq)            |               109 |                   154 |              98 |      |       77 |        130-160 |
| Ca (mEq)            |                 3 |                       |                 |      |          |                |
| Mg (mEq)            |                   |                       |               3 |      |          |                |
| Lactate (mEq)       |                28 |                       |                 |      |          |                |
| Acetate (mEq        |                   |                       |              27 |      |          |                |
| Gluconate (mEq)     |                   |                       |              23 |      |          |                |
| Glucose (mg/dL)     |                   |                       |                 | 4545 |     4545 |                |
| Osmolarity (mOsm/L) |               273 |                   308 |             294 |  252 |      406 |            309 |
| pH                  |               6.5 |                   5.0 |             5.0 |  4.0 |      4.5 |        6.4-7.4 |
| Other               |                   |                       |                 |      |          | 50 g/L albumin |

[Yunos et al JAMA 2012 study:](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)

- **Design:** Prospective open, label sequential study of 760 ICU patients (control) and 773 ICU patients (study group) at single hospital in Melbourne, Australia
- **Control period:** Standard IVF per physician preference
- **Study period:** Chloride-rich IVF (0.9% saline, 4% succinylated gelatin solution, 4% albumin) became restricted and required specialist approval. Standard fluids allowed were chloride-restrictive fluids (Hartmann solution – similar to Lactated Ringer’s, Plasma-Lyte 148, chloride-poor 20% albumin)

|                                                                            |  Control period (Chloride-liberal) | Study period (Chloride-restricted)  |  P value  | Odds ratio for Cl-restrictive  fluid use |
| -------------------------------------------------------------------------- | ---------------------------------: | ----------------------------------: | --------: | ---------------------------------------: |
| Mean serum Cr increased in umol/L                                          |                  22.6 (0.26 mg/dL) |                   14.8 (0.17 mg/dL) |       0.3 |                                          |
| Incidence of injury & failure class for "acute kidney injury" (RIFLE defn) |                                14% |                                8.4% | &lt;0.001 |                                     0.52 |
| Use of renal replacement therapy (RRT)                                     |                                10% |                                6.3% |     0.005 |                                     0.52 |

**Bottom line:** Chloride-rich IV fluids were associated with greater acute kidney injury and need for RRT in ICU patients, compared to chloride-restrictive IV fluids. 

**NOTE:** There was, however, NO difference in mortality, hospital, ICU length of stay, or RRT after hospital discharge.

## References

- Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M. Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA. 2012 Oct 17;308(15):1566-72. doi: 10.1001/jama.2012.13356. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/?term=23073953)]
- http://www.medscape.org/viewarticle/503138 [[Source](http://www.medscape.org/viewarticle/503138%20)]
